Latest Stayble Therapeutics News & Updates

See the latest news and media coverage for Stayble. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Stayble Therapeutics (Stayble)

Clinical-stage biopharmaceutical company

staybletherapeutics.com
Headquarters
Gothenburg, Sweden
Founded year
2015
Company type
Partnership
Number of employees
5–10

Last updated

Latest news about Stayble Therapeutics (Stayble)

In short: Stayble Therapeutics narrowly avoided liquidation after shareholders voted to continue operations despite significant financial challenges.

Company announcements

  • Stayble

    Stayble presents Q3 report in webcast

    Stayble and FinWire host the event on 19 November at 13:00.

  • Stayble

    Stayble Therapeutics announces half-year report for 2025

    The report summarizes costs of 3 948 KSEK, result -3 921 KSEK and progress for STA363 towards phase 2 trial. Share issue added 4.55 MSEK.

  • Stayble

    Stayble publishes half-year report Q2 2025

    The company carries out directed issue, reduces costs and prepares STA363 for phase 2 study. Operating result improves to -3.9 MSEK.

  • Stayble

    Stayble Therapeutics holds annual general meeting

    The meeting approves the accounts for 2024, grants discharge of liability, re-elects the board of directors and auditor, resolves on fees and amends the articles of association. It was held on June 5, 2025.

Unlock all announcements with a

Media coverage

  • Dagens industri

    Member in Stayble leaves with immediate effect

    Erik Kinnman leaves the board of Stayble Therapeutics, at his own request and with immediate effect.

  • Life Science Sweden

    UPDATED: Stayble continues operations - but life science profile jumps off

    Stayble Therapeutics continues to drive its business forward. An extraordinary general meeting on Thursday said no to putting the company into liquidation. At the same time, board member Erik...

  • Life Science Sweden

    Distressed Gothenburg company wants to sell intangible assets

    The research company Stayble Therapeutics has called an extraordinary general meeting on May 7 to decide on voluntary liquidation, alternatively continued operations.

  • Life Science Sweden

    Stayble Therapeutics' board proposes voluntary liquidation and delisting

    The shareholders in the research company Stayble Therapeutics are called to an extraordinary general meeting, also the first control meeting, on Thursday, May 7 in Gothenburg.

Unlock all articles with a

Never miss news about Stayble

Track Stayble and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.